IsomiR Utility in Amyotrophic Lateral Sclerosis Prognostication

Yahel Cohen[1,2#], Ilan Sinai[1,2#], Iddo Magen[1,2#], Yehuda Matan Danino[1,2], Joanne Wuu[3], Andrea Malaspina*[4], Michael Benatar*[3], Eran Hornstein[1,2*†]

[1]Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel,
[2]Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel
[3]Department of Neurology and ALS Center, University of Miami Miller School of Medicine, Miami, FL, USA
[4]UCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, UK

[#] These authors contributed equally
[*] Corresponding authors
[†] Lead corresponding author

Correspondence:
Andrea Malaspina (a.malaspina@ucl.ac.uk) and Michael Benatar (mbenatar@med.miami.edu) are corresponding authors for the ABC and PGB cohorts, respectively. Eran Hornstein (eran.hornstein@weizmann.ac.il) is the corresponding author for all other facets of the work.

Summary

Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron loss. IsomiRs are microRNA (miRNA) isoforms that arise from alternative processing or editing events during miRNA biogenesis. While isomiRs may carry distinct biological and clinical relevance, their potential as cell-free biomarkers in neurodegeneration remains largely unexplored.

Method: Here we investigated the prognostic utility of plasma isomiRs in ALS, using next-generation sequencing and two orthogonal statistical approaches.

Findings: We profiled cell-free isomiRs in 154 ALS patients from a British cohort and identified higher levels of one isomiR, let-7g-5p.t, to be associated with longer survival. This finding was independently validated in an international ALS cohort of 200 patients. let-7g-5p.t prognostic utility was comparable to that of neurofilament light chain (NfL) or miR-181.

Conclusion: These results establish isomiRs as a novel class of blood-based biomarkers in ALS with potential to refine prognostication in clinical trials for neurodegenerative diseases.

Funding: Target ALS, Israel Science Foundation (ISF 3497/21, 424/22) and the CReATe Consortium. All additional funding can be found in the Acknowledgements section of this paper.

Keywords

Prognostic biomarkers, neurodegenerative diseases, Amyotrophic Lateral Sclerosis, miRNA, isomiRs, survival analysis, translational neuroscience, machine learning in biomedicine, small RNA biomarkers.

Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the human motor neuron system. Heterogeneity of patient progression rate[1] challenges the detection of therapeutic effects in clinical trials[2]. Biofluid-based biomarkers have garnered increasing attention as tools to monitor progression[3,4]. These include urinary p75[5], troponin T2[6] and microRNAs (miRNAs)[7]. Additionally, neurofilament light chain protein (NfL)[8] is a strong predictor of the rate of disease progression, conveying meaningful prognostic information. Accordingly, we have recently demonstrated the utility of NfL in reducing the sample size required for clinical trials in a trial-like population[9]. miRNAs are small endogenous RNAs that contribute to post-transcriptional silencing of mRNA[10]. miRNAs are critical for motor neuron viability[11] and their biogenesis is known to be dysregulated in ALS[12-16]. Previous studies have shown that cell-free miRNAs and in particular miR-181 might have prognostic value[7,17]. miRNA biogenesis is a multistep process that starts with the transcription of a primary miRNA, which is cleaved by the nuclear microprocessor complex to yield an intermediate double-stranded hairpin precursor (pre-miRNA)[18]. After export of the pre-miRNA from nucleus to cytoplasm, it is cut by Dicer, creating a single strand 22nt guide that is loaded on to the RNA-induced silencing complex (RISC)[19]. IsomiRs display sequence variations that distinguish them from the reference sequence miRNAs (reference miRNA), including 3' or 5' sequence changes, or sequence polymorphism[20-22]. IsomiR production is often the result of aberrant miRNA biogenesis and isomiR levels in tissues or biofluids are often low and heterogeneous[23].

Mutations in the genes encoding for a handful of RNA binding proteins were found to be linked to increased risk of developing ALS, including Fused in Sarcoma (FUS)[24,25], and TAR DNA-binding protein 43 (TDP-43)[26]. Cytoplasmic mislocalization of TDP-43 into inclusions and loss of its nuclear function are reported in approximately 97% of patients[27]. Accordingly, cryptic exon splicing impacts dozens of mRNAs[28-30], some of which may have value as novel biomarkers relevant to ALS therapy development[31,32]. Interestingly, loss of TDP-43 or FUS also leads to dysregulation in isomiR profiles or miRNA biogenesis[33,34]. Furthermore, miRNA biogenesis proteins, Drosha and Dicer, were suggested to be involved in the disease[11,12,35]. Taken together, changes in isomiRs may be directly or indirectly related to ALS. The potential of cell-free isomiRs as biomarkers has been suggested in cancer[36-40] and in a recent work of Loher et al.[41]. In this work the authors provided profiles and performed analysis of transfer RNA-derived fragments (tRFs), ribosomal RNA-derived fragments (rRFs), Y RNA-derived fragments, and isomiR alterations in ALS plasma of a single cohort. Loher et al. found dozens of small non coding RNAs with diagnostic and prognostic potential. Here, we test the

value of isomiRs for ALS prognostication. We profiled cell-free isomiRs in a British cohort of 154

patients with ALS. Using Cox proportional hazard regression[42-44] and orthogonally machine learning

(ML) survival prediction[42,44-47], we identified 18 isomiR predictors, which were successfully replicated

in an independent international cohort of 200 patients. We further demonstrate that isomiR-let-7g-5p.t

particularly carries prognostic value, with potential to complement established clinical features and

previously described biomarkers, such as miR-181 and NfL. These findings establish isomiR as a

novel family of biomarkers for neurodegeneration and highlight their potential as reliable predictors of

ALS survival.

84 Results

85 Study population and baseline characteristics

We conducted our study in two independent cohorts of patients with ALS. Clinical data and

blood samples were obtained for 154 patients from the ALS biomarker cohort (UK)[48], and for 200

patients from the Phenotype Genotype Biomarker (PGB) study[49]. Clinical and demographic cohort

characteristics are summarized in **Table 1.** We found the discovery and replication cohorts to be

clinically comparable in DeltaFRS (Mann-Whitney P-value = 0.18, **Figure 1A**), baseline ALSFRS-R

score (Mann-Whitney P-value = 0.24, **Figure 1B**), site of symptom onset (χ^2 goodness of fit P-value =

0.08, **Figure 1C**), Riluzole treatment (χ^2 goodness of fit P-value = 0.34, **Figure 1D**), and C9orf72

repeat expansion status (χ^2 goodness of fit P-value = 0.6). Imbalances in patients' sex distribution (χ^2

goodness of fit P-value = 0.009, **Figure 1E**) and age were noticed (t-test P-value ≤ 0.001, **Figure 1F**).

The number of censored events were also statistically different between the cohorts (9% vs 54% in

UK and PGB, respectively, χ^2 goodness of fit P-value ≤ 0.001, **Figure 1G**).

Our study explores isomiRs, which are sequence isoforms of miRNAs that arise from

differences in processing, editing, or modifications of miRNA precursors (**Table S1** for nomenclature;

Figure 2A), as ALS prognostic biomarkers. Here we use the term "reference miRNA" to refer to the

most abundantly expressed (predominant) sequence variant among all isomiRs derived from a given

miRNA gene. Noteworthy, the literature refers to a "miRNA" as the collective set of all dozens of

annotated isomiRs[20].

Sequencing and data preprocessing were conducted in parallel across 154 and 200 patient

samples from the UK and PGB cohorts, respectively. Following noise filtration, 1,480 isomiRs from

287 miRNA genes were co-identified in both the discovery and replication cohorts. The discovery
isomiRs study was performed on the UK cohort, whereas the PGB was held out as an unseen,
independent replication cohort.

isomiR-let-7g-5p.t levels differentiate between short and long survival

To identify potential isomiRs associated with patient survival, we dichotomized the 1480
isomiRs that were shared between cohorts, based on their median abundance in the UK discovery
cohort. A univariate Cox regression, used to assess the association between isomiR expression and
time to death, revealed 290 statistically significant isomiRs (P-value ≤ 0.05), of which 16 remained
significant after correction for multiple comparisons (FDR ≤ 0.05, **Figure 2B**). Levels above median of
15 isomiRs were associated with decreased rate of mortality in patients (univariate Cox, Hazard ratios
(HR) < 1, 95% confidence interval (CI) = 0.34–0.77, FDR ≤ 0.05; **Figure 2C**), and levels above
median of one isomiR were associated with increased rate of mortality (univariate Cox, HR = 1.8,
95% (CI) = 1.32–2.6, FDR ≤ 0.05; **Figure 2C**). Next, we tested these associations in the PGB
replication cohort by dichotomizing isomiR levels, using the threshold obtained in the UK discovery
cohort. Only levels above median (≥246 unique molecular identifier (UMI) counts) of isomiR-let-7g-
5p.t were found to be associated with decreased rate of mortality in the PGB replication cohort
(univariate Cox, HR = 0.6, 95% CI = 0.39–0.91, P-value = 0.015; **Figure 2D**). In addition, levels
above median of isomiR-let-7g-5p.t were significantly associated with longer survival in the UK
discovery cohort (log rank, χ^2 = 18.7, P-value ≤ 0.001, median survival difference = 8.2 months;
Figure 2E), and in the PGB replication cohort (log rank, χ^2 = 5.99, P-value ≤ 0.01, median survival
difference = 9.1 months; **Figure 2F**). Mean isomiR-let-7g-5p.t levels were significantly different in the
UK discovery sub cohorts, defined by plasma isomiR-let-7g-5p.t levels that are either higher or lower
than the median isomiR-let-7g-5p.t plasma value (351 vs. 176 UMIs in the above- and below-median,
Mann-Whitney P-value ≤ 0.001,**Figure S1A**). We found a similar difference in the PGB replication
sub cohorts (324 vs. 198 UMIs, Mann-Whitney P-value ≤ 0.001, **Figure S1A**).

Post division by median levels, the sub-cohorts were clinically comparable within each cohort.
Age at symptom onset (Mann-Whitney P-value ≥ 0.1, **Figure S1B**), Age at enrollment (Mann-Whitney
P-value ≥ 0.08, **Figure S1C**), baseline ALSFRS-R score (Mann-Whitney P-value ≥ 0.27, **Figure
S1D**), DeltaFRS (Mann-Whitney P-value ≥ 0.13, **Figure S1E**), sex distribution (χ2 goodness of fit P-
value ≥ 0.1, **Figure S1F**), site of symptom onset (χ2 goodness of fit P-value ≥ 0.2, **Figure S1G**),
Riluzole treatment (χ2 goodness of fit P-value ≥ 0.15, **Figure S1H**), and C9orf72 repeat expansion

status (7 vs 5 and 8 vs 12 carriers in above/below median groups, respectively, in each cohort, $\chi 2$

goodness of fit P-value ≥ 0.6). Therefore, isomiR-let-7g-5p.t levels stratify patients independently of

key clinical variables.

We sought to compare the mortality rate associated with isomiRs and the respective miRNAs,

which reflect the aggregate of dozens of expressed isomiRs assigned to a miRNA gene. While

isomiR-let-7g-5p.t levels were associated with decreased mortality rate, no cognate miRNA was

significantly associated with mortality rate in both cohorts, including let-7g-5p (univariate Cox, HR =

0.87, 1.1; 95% CI = 0.63–1.2, 0.65-1.8; P-value > 0.05 in both, respectively, **Table S2**). Accordingly,

plasma levels of cognate miRNA let-7g-5p did not differentiate between short and long survival in the

UK discovery or the PGB replication cohorts (log rank χ^2 = 0.63, 0.09; P-value > 0.05 in both, median

survival difference = 0.3, 3.8 months, respectively; **Figure 2G, H**).

IsomiR-let-7g-5p.t is the best prognostication isomiR in two independent ALS cohorts

Although isomiR-let-7g-5p.t emerged as a promising candidate for ALS prognostication, the high

dimensionality of our dataset motivated us to explore the predictive performance of isomiR

combinations and their potential non-linear interactions using ML, as employed in our previous

studies[50]. We sampled at random subsets of 20 isomiRs, with repetition, using bootstrapping, so each

isomiR within the pool of 1480 would be included in at least 50 distinct subsets. To mitigate the risk of

false positive discoveries inherent in large-scale analyses, the 154 patients of the UK discovery

cohort were divided randomly into 10 bins, and a Sequential forward selection (SFS) with 10-fold

cross-validation (CV) technique was performed for each of the isomiR subset[51,52]. 84 isomiRs were

selected within 90% of the subsets in which they were included after SFS (≥45 out of 50, with Cox

regression[42], random survival forest (RSF)[44], gradient survival boosting (XGB)[43], **Figure S2A**). Of the

three orthogonal survival models, XGB demonstrated the highest mean concordance index score (C-

index) across the 84 isomiRs (**Figure S2B**).

Next, we modeled survival of the 84 isomiRs by XGB. IsomiRs were included if their subsets

displayed a C-index higher than a threshold that was defined empirically by the elbow method[53] (>

C-index of 0.74). Reassuringly, isomiR-let-7g-5p.t was detected, along with 17 other isomiRs: isomiR-

let-7e-5p.G9C, isomiR-let-7f-5p.T16C.t, isomiR-let-7i-5p.G5A, isomiR-130b-5p.T, isomiR-142-3p.a,

isomiR-451a.T.A, isomiR-144-3p, isomiR-146a-5p.T22A, isomiR-151a-3p.A9G, isomiR-25-3p.A22T,

isomiR-30d-5p.A20G.CT, isomiR-425-5p.as, isomiR-432-5p, isomiR-486-5p.C, isomiR-486-5p.T9G.T,

isomiR-92a-3p.T1C, isomiR-92a-3p.T22C (**Figure S2C**).

After hyperparameter tuning with 5-fold CV (Supplementary Methods), a model based on

these 18 isomiRs demonstrated strong prognostic capacity across patient survival duration of 84

months (time-dependent area under the curve (AUC(t)) values of 0.7 to 0.95; average 0.78; C-index =

0.7; survival duration 2 - 85 months; **Figure 3A**), but survival prediction was less effective in the PGB

replication cohort (AUC(t) 0.49- 0.9, average 0.62; C-index = 0.55; survival duration 3–54 months;

Figure 3A). Notably, prediction was better for patients with longer survival times. Additionally, miRNA

and reference miRNA displayed poor performance over time (**Figure 3B, C**).

We demonstrate higher performance with the model trained on the 18 selected isomiRs

relative to models trained on the collective set of all annotated isomiRs (the "miRNA", average AUC(t)

= 0.64/0.53, C-index= 0.59/0.52 in the UK discovery and PGB replication cohorts, respectively) or the

most abundant isomiR ("reference miRNAs" average AUC(t)= 0.68/0.46, and C-index = 0.63/0.47,

Figure 3D, E).

To identify the isomiRs most valuable for survival prediction, we calculated Shapley Additive

Explanations (SHAP) for the model average risk function. High levels of isomiR-let-7g-5p.t were

associated with reduced risk of death and longer survival (**Figure 3F**). In contrast, high levels of

isomiR-92a-3p.T22C, isomiR-92a-3p.T1C, isomiR-let-7f-5p.T16C.t, and isomiR-let-7i-5p.G5A

associate with higher risk and shorter survival. A similar SHAP analysis of the PGB replication cohort

was highly correlated, highlighting the model's robustness (**Figure 3G**). We then derived the HRs

from SHAP values, as previously described[54]. IsomiR-92a-3p.T22C and isomiR-let-7g-5p.t levels

were associated the most with increased / decreased mortality, respectively (**Figure 3H**).

As isomiR expression can vary across cohorts, we assessed abundance and inter-cohort

correlation to evaluate biological reproducibility. Among the 18 selected isomiRs, mean expression

ranged from 4–9 UMIs (UK cohort), and 5–14 UMIs (PGB cohort) and the detection rates were

comparable between cohorts (**Figure S3A, B**). IsomiR-142-3p.a had the highest expression (UK =

974 ± 833 UMIs, PGB = 1984 ± 945 UMIs), followed by isomiR-let-7g-5p.t (UK discovery cohort:

264 UMIs ± 129; PGB replication cohort: 259 UMIs ± 94). IsomiR abundance was well correlated

between cohorts (r = 0.74, P = 8.1e–28, **Figure S3C, D**) but no correlation was noted between the

abundance of isomiRs and their "cognate miRNA", nor with the "reference miRNA" (**Table S3**).

Lower isomiR-let-7g-5p.t levels in ALS blood relative to non-neurodegeneration controls

Having found that isomiR-let-7g-5p.t holds prognostic value for ALS in two orthogonal

approaches, we compared its levels between patients and controls. To do so, we reanalyzed plasma

samples from two independent control cohorts from Queen Mary hospital (QMUL - CTL) and

University College London (UCL - CTL). IsomiR-let-7g-5p.t levels were comparable across the two

ALS cohorts within the same sub cohort (mean difference ≤ 27 UMI, Tukey honestly significant

difference [HSD] P-value ≥ 0.99, **Figure S4**), and although variable across control cohorts (mean

difference = 324, Tukey HSD P-value ≤ 0.001), we observed significantly lower levels in the below-

median ALS sub cohorts compared to both controls and the above-median ALS sub cohorts (mean

difference ≥ 369 UMI and mean difference ≥ 522 UMI, respectively, Tukey HSD P-value ≤ 0.001,

Figure S4). Therefore, isomiR-let-7g-5p.t is also of potential diagnostic value.

Lastly, after examining isomiR-let-7g-5p.t biomarker potential, we tested if there was a change

in the isomiR's predicted targets compared to its reference miRNA. We retrieved the predicted targets

of miRNA let-7g-5p from miRCarta[55], subjected them to a miRNA-mRNA hybridization prediction

algorithm[56] and compared to the reference miRNA let-7g-5p and isomiR-let-7g-5p.t. Out of potential

~4000 mRNA targets, 3189 had at least one significant hybridization site with either the reference

miRNA let-7g-5p or isomiR-let-7g-5p.t. 358 out of 3189 mRNA targets were predicted to lose at least

one hybridization site, and 43 were predicted to gain at least one such isomiR-let-7g-5p.t site

(Wilcoxon p-value = 2.4e-47, rank-biserial correlation effect size = 0.67). Enrichment for targets

associated with ALS was not noticed.

Prognostic Value of Plasma isomiR-let-7g-5p.t in ALS Is Comparable to NfL

As we previously reported[17,57], high (above median) blood NfL levels were significantly

associated with shorter survival in the UK discovery cohort (log-rank, χ^2 = 9.4, P-value = 2e-3,

median survival difference = 7.1 months; **Figure 4A**), and this was consistent in the PGB replication

cohort, when NfL dichotomized according to the median plasma value in the UK cohort (log rank, χ^2 =

17.7, P-value = 2.7e-5, median survival difference = 13.7 months; **Figure 4B**). Above-median NfL

levels were associated with an increased mortality rate in both cohorts (UK discovery cohort:

univariate Cox, HR = 1.7, 95% CI = 1.2-2.3, P-value = 2.4e-4, C-index = 0.56 ; PGB replication cohort

Cox HR = 2.4, 95% CI 1.6-3.7, P-value = 4.5e-6, C-index = 0.63; **Figure 4C, D**). In contrast, higher

levels of seven (out of eighteen selected by ML, **Figure S3C**) isomiRs were associated with a
decreased mortality rate (univariate Cox, HR < 0.72, 95% CI = 0.37-0.99, P-value ≤ 0.05, C-index >
0.54; **Figure 4C**). However, only isomiR-let-7g-5p.t retained significant HR in univariate Cox
regression in the PGB replication cohort (UK discovery cohort: HR = 0.58, 95% CI = 0.41-0.81, P-
value = 1.4e-3, C-index = 0.57; PGB replication cohort: univariate Cox, HR = 0.6, 95% CI = 0.4-0.9,
P-value = 0.015, C-index = 0.55; **Figure 4C, D**). Accordingly, isomiR-let-7g-5p.t was the only isomiR
that significantly distinguishes short and long survival times in both cohorts, using the log-rank test
(**Figures S5A, B**).
250
In multivariate Cox analysis, NfL remained significantly associated with increased mortality
rate in both cohorts (UK discovery HR = 1.7, 95% CI = 1.2-2, P-value = 6e-4; PGB replication HR =
3.3, 95% CI = 2.4-5.3, P-value = 2e-7), whereas isomiR-let-7g-5p.t was significant only in the PGB
cohort (multivariate Cox, HR = 0.52, 95% CI = 0.32-0.86, P-value = 0.01; **Figure S6A, B**).
Noteworthy, isomiRs modestly improved the prognostic capacity, compared to a model which only
includes NfL, in both cohorts (C-index = 0.67/0.72 in UK discovery or PGB replication, respectively,
compared to 0.56/0.63 for NfL alone).
258
When considering only isomiR-let-7g-5p.t and NfL together, isomiR-let-7g-5p.t showed a
stronger association with risk of mortality than NfL in the UK discovery cohort (HR of NfL in a
multivariate Cox model = 1.64, 95% CI = 1.2-2.3, P-value = 3.9e-4; HR of isomiR-let-7g-5p.t in a
multivariate Cox model = 0.49, 95% CI = 0.35-0.69, P-value = 3.8e-6; **Figure S6C**). Together, NfL
and isomiR-let-7g-5p.t yield better prognostication than either marker alone (multivariate Cox C-index
= 0.63 vs. C-index = 0.56 for NfL alone or C-index = 0.59 for isomiR-let-7g-5p.t alone). In the PGB
cohort, NfL had a stronger association with mortality rate (NfL multivariate Cox, HR = 3, 95% CI =
1.9-4.6, P-value = 1e-7; isomiR-let-7g-5p.t multivariate Cox, HR = 0.46, 95% CI = 0.29-0.7, P-value =
4.8e-5; **Figure S6D**). Nonetheless, both markers together improved survival prediction compared to
either one individually (multivariate Cox C-index = 0.67, for NfL alone C-index = 0.63, for isomiR-let-
7g-5p.t alone C-index = 0.56). Moreover, when combined with relevant clinical features (baseline
ALSFRS-R, site of symptom onset, age at onset), only isomiR-let-7g-5p.t (UK discovery multivariate
Cox, HR = 0.53, 95% CI = 0.38-0.75, P-value = 3e-5; PGB replication multivariate Cox, HR = 0.52,
95% CI = 0.33-0.83, P-value =6.5e-3) and baseline ALSFRS-R (UK discovery multivariate Cox, HR =
0.97, 95% CI = 0.94-0.99, P-value = 2.6e-3; PGB replication multivariate Cox, HR = 0.96, 95% CI =
0.92-0.99, P-value = 0.013) were significantly associated with mortality risk in both cohorts (**Figure
S6E, F**). In contrast, NfL levels association with mortality were only approaching significance in the

UK discovery cohort (multivariate Cox, HR = 1.4, 95% CI = 0.97-1.94, P-value = 0.08; **Figure S6E**),

while being significantly associated with mortality in the PGB cohort, with an effect size larger than

that of isomiR-let-7g-5p.t (multivariate Cox, HR = 2.5, 95% CI = 1.5-4, P-value ≤ 0.001; **Figure S6F**).

Since above-median levels of isomiR-let-7g-5p.t and NfL were associated with opposing

effects on mortality risk, we next assessed joint prognostic capacity, by calculating the ratio between

isomiR-let-7g-5p.t and NfL levels. High values of this ratio slightly improved distinction between short

and long survival compared to NfL alone (UK discovery log-rank, χ^2 = 11.8, P-value = 5.9e-4, median

survival difference = 8 months; PGB replication log-rank, χ^2 = 19.8, P-value = 8.8e-6, median survival

difference = 14 months; **Figures 4E, F**). Notably, the ratio showed a stronger inverse association with

mortality risk compared to either marker alone, and improved overall prognosis (UK discovery

univariate Cox, HR = 0.56, 95% CI = 0.4-0.78, P-value = 6.2e-4, C-index = 0.58; PGB replication

univariate Cox, HR = 0.4, 95% CI = 0.26-0.6, P-value = 1.8e-5, C-index =0.64 ;**Figure S6G**). Taken

together, these results suggest that isomiR-let-7g-5p.t performs comparably to NfL, and that

combining isomiR-let-7g-5p.t with NfL improved predictive performance, at least as reflected by the

C-index. These findings highlight the value of isomiR-let-7g-5p.t as a potential prognostic biomarker

in ALS.

Prognostic Value of Plasma isomiR-let-7g-5p.t in ALS Is Comparable to miR-181

The UK cohort was a subset of the cohort where we originally discovered miR-181, a

multiplication of sister miRNAs miR-181a-5p and miR-181b-5p, as a prognostic marker[17]. A univariate

Cox analysis revealed that high miR-181 levels were associated with a >2.1-fold increased risk of

mortality, again demonstrating that isomiR-let-7g-5p.t has an equivalent prognostic capacity to

previously published markers (UK discovery cohort HR = 2.1, 95% CI = 1.4–3.2, P-value ≤ 0.001, C-

index = 0.58; PGB replication cohort HR = 3.0, 95% CI = 1.7–5.4, P-value ≤ 0.001, C-index = 0.55;

Figure 4C, D).

miR-181 levels distinguished between short and long survivors in the UK cohort (log rank on

dichotomized miR-181 levels: χ^2 = 13.7, P-value = 2.1e-4, median survival difference = 7.2 months;

Figure 5A), and also in the PGB cohort (log rank: χ^2 = 15.1, P-value = 1e-4, median survival

difference = 9.7 months; **Figure 5B**). Notably, isomiR-let-7g-5p.t was the only isomiR to remain

statistically significant in both cohorts, in a combined analysis of miR-181 and the 18 isomiR chosen

by ML (UK discovery multivariate Cox, HR = 0.63, 95% CI = 0.4-0.98, P-value = 0.04; PGB replication

multivariate Cox, HR = 0.57, 95% CI = 0.36-0.9, P-value = 0.017; **Figure 5C, D**). To assess joint

prognostic capacity of isomiR-let-7g-5p along with miR-181, we tested isomiR-let-7g-5p / miR-181

ratio capacity to distinguish between short and long survival. We found a significant association of the

ratio levels to patient survival in both cohorts (UK discovery log rank: χ^2 = 20.6, P-value = 5.6e-6,

median survival difference = 8 months; PGB replication log rank: χ^2 = 7, P-value = 8e-3, median

survival difference = 6 months; **Figures 5E, F**). Moreover, the HR of isomiR-let-7g-5p / miR-181 ratio

was 0.38 in the discovery and 0.44 in the replication cohort (UK discovery univariate Cox, 95% CI =

0.19–0.77, C-index = 0.58, P-value = 8e-6; PGB replication univariate Cox, 95% CI = 0.18-0.8, C-

index = 0.53, P-value = 0.01, **Figure S6G**). Taken together, these results highlight the potential of

isomiR-let-7g-5p.t as a robust biomarker for ALS survival.

Discussion

IsomiRs display small variations of either sequence insertion, deletion, or single nucleotide

polymorphism that distinguish them from the reference miRNA form. While miRNAs are extensively

studied in ALS[12,14-17,58-67], we are first to demonstrate the value of isomiRs as biomarkers for

neurodegeneration in two large, independent cohorts. Among 1480 studied isomiRs, isomiR-let-7g-

5p.t emerges as the most promising prognostic biomarker. High plasma levels of isomiR-let-7g-5p.t

are significantly associated with lower mortality rate and longer survival. This effect was not explained

by clinical characteristics, suggesting that the information encompassed in isomiR-let-7g-5p.t is not

directly associated with a single clinical feature. IsomiR-let-7g-5p.t levels were reduced in two ALS

cohorts relative to two control cohorts, suggesting diagnostic potential. Higher plasma levels of

isomiR-let-7g-5p.t are comparable but reciprocal to miR-181 and NfL, which we previously associated

with ALS prognosis[9,17,57]. Additionally, the incorporation of isomiR-let-7g-5p.t to either miR-181 or NfL

enhances their prognostic value.

Dysregulation of miRNAs in ALS has previously been demonstrated in mice and

humans[11,15,16]. Numerous studies have proposed miRNA utility as potential biomarkers for prognosis

for ALS [7,61,65]. However, isomiRs have been overlooked in part due to their sequence heterogeneity

and their low abundance[23]. Nevertheless, our work, the work of Loher et al.[41], and notable

dysregulation of RNA-binding proteins such as TDP-43, DICER, DROSHA, or FUS in ALS[11,12,34,68,69]

should prompt additional studies of isomiRs in ALS. In addition, it is possible that isomiRs play a role

in other neurodegenerative disorders, with implications ranging from basic research, to clinical
applications.

Our analysis found that isomiR-let-7g-5p.t accounts for approximately 40% of the reads of let-
7g-5p in the plasma and perhaps predominates the let-7g-5p repertoire. In this context, microRNA let-
7g-5p has previously been reported to be lowered in abundance in the blood of patients with sporadic
ALS (sALS)[65], and in patients with frontotemporal dementia (FTD) due to a *C9orf72* repeat
expansion, compared to healthy controls[70]. Loher et al[41] reported hundreds of differentially abundant
isomiRs in ALS patient plasma compared to controls, with roughly equal numbers up- and down-
regulated. 53 out of 56 Let-7 family isomiRs were elevated in ALS. The association of reduced
plasma isomiR-let-7g-5p.t levels to severe disease, observed in our study, suggests a distinct
behavior not captured by Loher et al[41]. Let-7g-5p blood levels are also decreased in individuals with
Alzheimer's disease (AD) or mild cognitive impairment (MCI)[71-78], and correlate with AD severity[71]. In
addition, let-7g-5p was found to be downregulated in brain samples of Huntington patients compared
to controls[79]. This could reflect a specific decrease that is mediated, at least in part, via isomiR-let-
7g-5p.t.

Members of the let-7 miRNA family have been repeatedly linked to neurodegenerative
diseases. In ALS, let-7d and let-7f are reduced in patient plasma, while let-7b is elevated in
leukocytes. In AD, several let-7 members, including let-7b, let-7d, let-7e, and let-7g, are upregulated
in patient biofluids or neuronal vesicles, with let-7b also correlating with disease progression. In
Parkinson's disease, let-7a and let-7f are decreased in plasma, whereas let-7g-3p is increased in
CSF-derived vesicles[66,80-90]. Together, these findings underscore the relevance of the let-7 family in
neurodegeneration and reinforce the significance of isomiR-let-7g-5p.t as a prognostic marker in ALS.

Seventeen other isomiRs displayed potential relevance in our analysis, though to a weaker
extent. Some of the miRNAs associated with these isomiRs (miR-451, miR-144-3p, and miR-486-5p)
are linked to oxidative stress and inflammation[91-99], which potentially play a role in neurodegeneration.
However, because we analyze the isomiRs in plasma, the tissue expression origin is unclear.

The mechanisms underlying isomiR levels, including isomiR-let-7g-5p.t, and their functional
role in disease progression is yet to be fully elucidated. The loss of a single nucleotide at the 3′ end
occurs outside the seed region and has limited impact on target specificity[100-103]. Accordingly, using

RNA22 v2[56], we found that a subset of predicted targets might interact differently with isomiR-let-7g-
5p.t relative to let-7g-5p, but no enrichment was observed for ALS-related pathways.

Together, our results highlight the potential of isomiR-let-7g-5p.t as a prognostic biomarker in
ALS, potentially offering comparable value to clinical features, miR-181, and NfL. Moreover, isomiR-
let-7g-5p.t enhances effective prognostication in conjunction with other markers. These findings
warrant further exploration of the utility of isomiR-let-7g-5p.t and other isomiRs in neurodegenerative
diseases.

Limitations of Study

Despite the promising prognostic potential of isomiRs in ALS, several limitations must be
noted: some uncertainty remains about the reference miRNA due to high sequence similarity within
the broad family of Let-7 miRNAs. Future advances in sequencing technologies and alignment
algorithms may improve isomiR resolution and assignment. We did not find any influence for sex on
the results of the study. Larger and more diverse population cohorts would strengthen the
generalizability of the findings and help assess the robustness of isomiRs across different ALS
subtypes, sex, or disease stage. Last, given the availability and strong prognostic performance of
NfL, the practical utility of isomiRs as standalone biomarkers may be limited until an effective way to
measure them is developed. These limitations highlight the need for continued research on isomiRs
in ALS.

394 Acknowledgments

Eran Hornstein is the Mondry Family Professorial Chair and Head of the Nella and Leon Benoziyo
Centre for Neurological Diseases and of the Andi and Larry Wolfe Centre for Neuroimmunology and
Neuromodulation. We acknowledge participants and families for their contributions. We thank ALS
biomarker cohort study (UK) and the CReATe consortium's Phenotype-Genotype biomarker (PGB)
study co-workers for their contributions to biobanking, genomics, biorepository, project management,
and data management. We thank Crown Genomics Team of Nancy and Stephen Grand Israel
National Center for Personalized Medicine for small RNA sequencing. The authors thank Dr. Isidore
Rigoutsos and Phillipe Loher (Thomas Jefferson University), for assistance with the revised
manuscript. This study was funded by several programs. Eran Hornstein lab is funded by the Andi
and Larry Wolfe Centre for Neuroimmunology and Neuromodulation; the Binational Science
Foundation (BSF); Association Française Contre les Myopathies (AFM grants 24882, 28680);

Muscular Dystrophy Association (MDA United States grant 1280000), Target ALS, Israel Science
Foundation (ISF 3497/21, 424/22, 3643/26), ALS Canada, ALS Association (United States), Minna-
James-Heineman Stiftung through, Minerva Foundation, with funding from the Federal German
Ministry for Education and Research, Robert Packard Center for ALS Research at Johns Hopkins,
McGill University, EU - ERA-Net, Radala Foundation for ALS Research. Additional support
generously provided by the Kekst Family Institute for Medical Genetics. Weizmann SABRA - Yeda-
Sela - WRC Program, the Estate of Emile Mimran, and The Maurice and Vivienne Wohl Biology
Endowment. Nella and Leon Benoziyo Center for Neurological Diseases, Goldhirsh-Yellin
Foundation. Dr. Sydney Brenner and friends, Weizmann - Center for Research on
Neurodegeneration. Redhill Foundation – Sam and Jean Rothberg Charitable Trust Dr. Dvora and
Haim Teitelbaum Endowment Fund, and Weizmann Institute Knell Family Institute for Artificial
Intelligence. The CReATe Consortium (U54NS092091) is part of the NIH Rare Diseases Clinical
Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS.
This Consortium is funded through a collaboration between NCATS and the NINDS. This work was
also supported by a Clinical Trial Readiness grant (U01NS107027) from NINDS and by a grant from
the ALS Association to support the CReATe Biorepository (grant ID 16-TACL-242).

Resource availability

Lead contact

425   Further information and requests for resources should be directed to and will be fulfilled by the lead
426   contact, Eran Hornstein (eran.hornstein@weizmann.ac.il)

Materials availability

428   This study did not generate new unique reagents.

Data and code availability

- The newly generated transcriptomic small RNA-seq datasets have been uploaded to GEO: https://www.omicsdi.org/dataset/geo/GSE298532 for ALS patients and GEO: https://www.omicsdi.org/dataset/geo/GSE307456 for controls. Additional data including clinical characteristics, NfL quantification, corrected transcriptomic data, feature level binarization, univariate Cox results, and ML feature selection results have been uploaded to Mendeley data: https://doi.org/10.17632/2xxw2f28p6.2).

436 • The custom code generated in this project, including data preprocessing, analysis, and
437   plotting, has been uploaded to Mendeley data: https://doi.org/10.17632/2xxw2f28p6.2).

438 • Any additional information required to reanalyze the data reported in this work paper is
439   available from the lead Contact upon request.

440
441

442 Author contributions

E.H., Y.C. and I.M. oversaw the conceptualization of this study, M.B., A.M. and J.W. recruited
participants and collected clinical data and biofluid samples. E.H., Y.C., I.M. & I.S. designed the study
and had unrestricted access to all data. Y.C. and I.M. oversaw molecular data collection. Y.C., I.M.
and I.S. performed, and replicated the statistical analyses with feedback from M.B. and J.W. E.H.
oversaw all facets of the study. Y.C., I.M, Y.M.D, M.B, A.M. and E.H participated in drafting the
manuscript, and all authors approved the final draft, and take full responsibility for its content,
including the accuracy of the data and the fidelity of the trial to the registered protocol and its
statistical analysis.

451 Declaration of interests

452 The authors declare no competing interests

453 Figures and tables titles and legends

Table 1. Clinical and demographic description of the study cohorts. Abbreviations: Baseline
ALSFRS-R - ALSFRS-R score at baseline assessment. DeltaFRS – change of ALSFRS-R score from
symptom onset to baseline assessment divided by months passed. Age at enrollment – age at
baseline assessment. Survival from symptom onset / enrollment – time from symptom onset or
baseline assessment to death/event censored. Censored event – number and percentage of right-
censored cases. SD standard deviation. Q1 - 25th percentile, Q3 - 75th percentile.

460
Figure 1 – Comparison of the UK discovery and PGB replication cohort metadata. **(A and B)**
Boxplot of **(A)** DeltaFRS, measured as the reduction in the ALSFRS-R score per month or **(B)**
baseline ALSFRS-R score at study enrollment. **(C – E)** Pie charts depicting **(C)** site of symptom onset
(SSO) **(D)** Riluzole treatment, or **(E)** sex **(F)** Boxplots of age at study enrollment and age at symptom

onset. **(G)** Pie charts showing the number of censored and deceased events for the UK discovery and
the PGB replication cohorts. *** P-value ≤ 0.001, two-sided Student's t-test.

Figure 2 – High plasma isomiR-let-7g-5p.t levels predict longer survival in patients with ALS.
(A) miRNA biogenesis yields several forms of miRNA isoforms (isomiRs). Following transcription, the
primary miRNA is cleaved by the nuclear microprocessor, exported as a precursor to the cytoplasm,
and further processed by Dicer into a ~22-nt guide RNA that is loaded onto RISC for target mRNA
binding and silencing. Variability in biogenesis, such as misplacement of processing factors, leads to
the generation of isomiRs. **(B)** Volcano plot of 1480 plasma isomiRs. Univariate Cox Hazard ratios
(HR, x axis) and significance (-$\log_{10}$p value; y axis). Red line denotes significance threshold (P-value
= 0.05). Only 16 isomiRs remained significant post multiple comparison correction (black line denotes
FDR = 5.2e-4). **(C and D)** Forest plots of univariate Cox proportional hazard ratios of the 16
significant isomiRs in UK discovery **(C)** or PGB replication **(D)** cohort (HR ≤ 0.6, or HR = 1.8, P-value
≤ 0.015). Only isomiR-let-7g-5p.t remained significant in both cohorts (denoted by green text). CI
denoted by a horizontal line. **(E and F)** Cumulative survival (Kaplan–Meier) curves for isomiR-let-7g-
5p.t in the UK discovery **(E)** or PGB **(F)** replication cohort. (UK: 77/77 patients in sub- vs. supra-
threshold cohorts; PGB: 104/96 patients in sub- vs. supra-threshold cohorts). **(G and H)** Kaplan–
Meier curves for the mature miRNA counterpart, let-7g-5p, in the UK discovery **(G)** or PGB **(H)**
replication cohort. (UK: 77/77 patients in sub- vs. supra-threshold sub cohorts; PGB: 40/160 patients
in sub- vs. supra-threshold; values used for dichotomization were the same in both cohorts).

Figure 3 – IsomiR based survival prediction in two independent cohorts. **(A-C)** Plots of AUC (y
axis) in the UK discovery (blue) or PGB replication (purple) cohorts for patient survival, as a function
of duration from enrolment (x axis) for isomiR **(A)**, cognate miRNA **(B)**, or reference miRNA **(C)**. **(D**
and E) Bar graphs of **(D)** average AUC across time (47/42 time points for patients from the UK
discovery or PGB replication, respectively), or **(E)** C-index for a model based on 18 selected isomiRs.
(F and G) SHAP analysis of the contribution of 18 isomiRs to risk prediction in the **(F)** UK discovery
or **(G)** PGB replication cohorts. Range of isomiR levels (low–blue to high–red). Positive or negative
SHAP values reveal higher or lower effect size of isomiR on the mortality risk (x axis), respectively.
(H) Plot of HR, calculated on the basis of XGB SHAP values according to Sundrani & Lu[54].

Figure 4 – IsomiR-let-7g-5p.t-based prognostication compared to NfL. **(A and B)** Cumulative
survival (Kaplan–Meier) curves for NfL plasma levels (76/76 sub-threshold (blue) /supra-threshold

(red) patients, respectively, from enrollment in the UK discovery cohort **(A)** and **(B).** NfL serum levels

(140/60 sub-threshold (blue) /supra-threshold (red) patients, respectively) in the PGB replication

cohort **(B)**. **(C and D)** Forest plots of univariate Cox proportional hazard ratios of 18 isomiRs, NfL and

miR-181 in **(C)** the UK discovery cohort or **(D)** the PGB replication cohort. NfL, miR-181 and isomiR-

let-7g-5p.t are highlighted in green. CI denoted by horizontal line. **(E and F)** Cumulative survival

(Kaplan–Meier) curves for isomiR-let-7g-5p.t/NfL ratio (76/76 sub-threshold (blue) / supra-threshold

(red) patients, respectively) from enrollment in **(E)** the UK discovery cohorts of **(F)** the PGB replication

cohort (53/147 sub-threshold (blue) / supra-threshold (red) patients, respectively)

Figure 5 – isomiR-let-7g-5p.t-based prognostication compared to miR-181. (A and B)

Cumulative survival (Kaplan–Meier) for miR-181 (122/32 sub-threshold (blue) / supra-threshold (red)

patients, respectively) in the UK discovery **(A)** or PGB replication (181 /19 patients sub-threshold

(blue) / supra-threshold (red) patients, respectively, **B)** cohorts. **(C and D)** Forest plots of multivariate

Cox proportional hazard ratios of 18 isomiRs and miR-181 in the UK discovery **(C)** or the PGB

replication **(D)** cohorts. IsomiR-let-7g-5p.t and miR-181 are highlighted in green. CI denoted by

horizontal line. **(E and F)** Cumulative survival (Kaplan–Meier) for isomiR-let-7g-5p.t/miR-181 ratio

(24/130 sub-threshold (blue) / supra-threshold (red) patients, respectively) from enrollment in the **(E)**

UK discovery cohort or **(F)** PGB replication cohort (11/189 sub-threshold (blue) / supra-threshold

(red) patients, respectively)

STAR★METHODS

Experimental model and subject details

Human samples

Study Cohorts

Two ALS patient cohorts were included.

ALS biomarker study (London, UK). This cohort consists of 154 British patients (REC Reference: 09/H0703/27, IRAS ID: 47352). Patients with neuroinflammatory or neurodegenerative disorders, recent injuries, systemic or organ-specific autoimmune disorders, or recent treatment with steroids, immunosuppressants, or immunoglobulins were excluded. Ethics approval was obtained from East London and the City Research Ethics Committee 1.

PGB study subset (CReATe Consortium). This cohort included 200 patients recruited from 12 U.S. sites and one South African site, as part of the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium (registered at clinicaltrials.gov NCT02327845) [9,49] Cognitive impairment (ALSci) or behavioral impairment (ALSbi) were determined by applying the revised Strong criteria[104] to Edinburgh Cognitive and Behavioral ALS Screen (ECAS[105]) data. Ethics approval was granted by the University of Miami central IRB (Internal Protocol ID #20160603), and by the University of Cape Town Health Sciences Human Research Ethics Committee in South Africa (REF number 165/2017).

Two control cohorts were analyzed.

ALS biomarker study controls. Ninety-nine adult individuals (72 females and 27 males, mean age 50.6 ± 13.2 years) recruited at Queen Mary Hospital, London (ethics approval 09/H0703/27).

UCL control cohort. Fifty-six adult individuals (30 females and 26 males, mean age 61 ± 13.3 years) from a longitudinal FTD cohort study at University College London (ethics approval 15/0805).

Controls were typically spouses or relatives of patients that were screened to confirm absence of neurological or neurodegenerative diseases.

All Patients were diagnosed with ALS by experienced ALS neurologists. Inclusion criteria to address a "trial-like" conditions were as follows: time from symptom onset to first blood draw shorter than 36 months, a baseline slow vital capacity (SVC) equal to or above 50%, and at least two study visits with measurement of the revised amyotrophic lateral sclerosis functional rating

549   scale (ALSFRS-R)[106]. All participants provided written consent (or verbal permission for a carer to

550   sign on their behalf) to be enrolled in the ALS biomarker study if they met inclusion criteria.

551   Participants information on sex, and age was self-reported. Information on gender, race, ethnicity

552   and socioeconomic status was not collected. All patients were de-identified.

554 Methods details

555 Clinical Assessments and Data Collection

Disease severity was assessed with the ALSFRS-R. The progression rate prior to enrollment

was estimated using the DeltaFRS, calculated by subtracting the ALSFRS-R score at baseline

assessment from a maximum score of 48, and dividing by the number of months passing from

symptom onset to baseline assessment. Any use of riluzole was recorded. Index date (follow-up "time

zero") was defined as the date of enrollment and survival time was measured from the index date to

events for either mortality, tracheostomy or permanent assisted ventilation (PAV). The censoring date

for survival analysis was documented in a case where an event was not observed before the study

ended. Experimenters were blinded during the steps of the molecular analysis. Whole blood was

collected by venipuncture in ethylenediaminetetraacetic acid (EDTA) tubes, and plasma was

recovered by centrifugation at room temperature (RT) for 10 min between 1300g-1750g. Plasma was

stored at < −70 °C prior to use Clinical information for patients is shown in Table 1.

569 Small RNA next-generation sequencing

The molecular experimenters were blinded to the identity of the samples. Total RNA was

extracted from 500µl plasma using miRNeasy Micro Kit following the manufacturer's protocol except

adding 2.5ml of Qiazol to each plasma sample (Qiagen, #217084). Samples were homogenized by a

30 second vortex. No biological or technical repeats were used. RNA was quantified with a Qubit

fluorometer using the RNA Broad Range Assay Kit (Thermo Fisher Scientific, #Q10211) following the

manufacturer's protocol. Small RNA next-generation sequencing libraries were prepared using the

QIAseq miRNA Library Kit (Qiagen, #331502) from 7.5 ng of total RNA following the manufacturer's

protocol. If RNA concentration was below the limit of detection, 5µl of undiluted RNA were used.

Precise linear quantification of miRNAs was achieved by 12-nucleotide long UMIs[107]. Samples were

randomly assigned to the preparation of libraries indexed with QIAseq miRNA NGS 48 Index IL

(Qiagen, #331595) and sequenced in batches of 48 or fewer samples. Library concentration was

determined with a Qubit fluorometer following the manufacturer's protocol (dsDNA High Sensitivity

Assay Kit, Thermo Fisher Scientific, #Q32854) and library size with TapeStation D1000 (Agilent).

Libraries with different indices were multiplexed and sequenced on a NextSeq 500/550 v2 (Illumina,

#20024906) or a NovaSeq 6000 flow cell (Illumina, #20028401), with a 75-bp single read or paired-

end reads with 6-bp index. FASTQ files were de-multiplexed using the user-friendly transcriptome

analysis pipeline[108]. Human miRNAs and isomiRs, as defined by miRBase - V22[109], were mapped

using CLC genomic workbench 22.0 (Qiagen) only to the positive strand. Reads were trimmed in two

consecutive fashions; Phred score[110], based error ($p_{error} = 10^{-\frac{Q}{10}}$) was calculated for every

nucleotide, high values reflect poor read quality. A trimming score defined by the subtraction of the

error from a threshold of 0.05 was set for each nucleotide. Then, a running sum of the nucleotide

errors was calculated per read. The region between the first positive value of the running sum and the

highest value of the running sum was kept with non-positive score reads being removed completely.

Consecutively, reads' ends were trimmed to keep the maximum length region containing 2 or fewer

ambiguous nucleotides. This was followed by the library's 3'-adaptors

(TGGAATTCTCGGGTGCCAAGG) trimming, with reads that did not contain any adaptors being

excluded from downstream analyses. Reads were filtered based on lengths of 15-55 bps. IsomiRs

were considered as 2bps changes (insertion, deletion, shift, and mismatch) up/downstream from

miRBase reference sequence with a maximum of 2 mismatches allowed in alignment. The algorithm

prioritizes perfect matches to reference miRNAs, followed by sequences of increasing mismatch

nucleotides. When a sequence aligns equally well to multiple isomiRs, counts are assigned uniformly

across all matching forms.

IsomiR definitions

604   Reference miRNA refers to the most abundantly expressed sequence variant among all isomiRs

605   derived from a given miRNA gene. The collective set of all isomiRs, often comprising around 50

606   distinct variants annotated for a specific miRNA gene is defined as the miRNA.

QC and pre-processing of sequencing data

Sequencing data were pre-processed separately for each cohort (British n=154 / PGB n=200)

and yielded ~280K/~228K isomiRs, respectively, but 99% of identified isomiRs were extremely rare

and sparsely detected across samples. Therefore, isomiRs were included in the analysis only if their

average expression level across cohort's samples was above 5 UMIs, yielding a total of 2046 and

2003 isomiRs in the British and PGB cohorts, respectively. As geometric mean cannot be calculated

with missing values, the remaining isomiR missing reads were imputed using multiple imputation with

a denoising autoencoder algorithm (parameters: 40 forward passes, three layers with 512 nodes

each, probability of corruption of 0.95, learning rate of $1e^{-6}$). Missing values were replaced by the

mean isomiR levels across 50 imputed datasets. Clinical features used for estimation of similarity

between patients: age, sex, site of symptom onset, and Riluzole treatment. Python-V3.9.2 and R-

V4.0.4 package *rMIDAS*-V.0.3[111] were used for the imputation. Using *DESeq2[112]*, libraries were

corrected for size by geometric mean, under the assumption that miRNA counts followed negative

binomial distribution[112]. Then, imputed values of original missing values were transformed back to

zero to avoid bias in batch correction. Finally, data were corrected for the library preparation batch to

reduce its potential bias by the R Combat function in *SVA*-V3.38 package[113]. Then, levels of 1480

isomiR identities shared across the two cohorts were standardized and isomiRs were considered for

downstream analyses.

Machine learning-based isomiR selection for disease prognostication

Biomarker discovery analysis (training) was performed using the UK cohort that we have

recently characterized[17] while the PGB cohort was reserved for external validation. The 1,480 isomiR

candidates were randomly sampled with repetitions to generate 3,718 bootstrap subsets, each

containing 20 isomiRs. The sampling process ensured that each isomiR was included in at least 50

distinct subsets. Importantly, any given subset contained one specific isomiR of interest alongside 19

other randomly selected isomiRs, resulting in at least 50 different subset compositions for each

individual isomiR. For each bootstrap set survival analysis was conducted using three survival

models: Cox regression analysis[42], RSF[44], and XGB[43]. The analyses were performed using the scikit-

survival library (version 0.23.0) in Python. SFS[114], adds iteratively isomiRs in different combinations to

optimize the C-index[115] (*mlxtend* library in Python).

The process explored approximately 1,000,000 possible combinations of isomiRs for each

subset $(\sum_{k=0}^{20} \binom{20}{k} = 2^{20} = 1,048,576)$, resulting in roughly 3.9 billion combinations across all 3,718

isomiRs subsets. Each isomiR combination was evaluated using 10-fold CV on subsets of the UK

discovery cohort within each of the three orthogonal survival models. A selection threshold of ≥90% in

the SFS process yielded 84 isomiRs. Subsequently, additional iterations of feature selection were

performed on the 84 isomiRs, generating 222 random subsets for further analysis. A C-index-based

threshold was determined using the elbow method[53] and applied across all random subsets. This

process identified two final panels, together consisting of 18 unique isomiRs, which were selected for
downstream analyses.

isomiRs panel prediction validation

After feature selection, an XGB model was trained on the UK discovery cohort to predict
patient survival time from enrollment. Hyperparameter tuning was conducted using 5-fold CV over
three rounds of *Optuna* optimization[116] (1000 trials per round, with a random sampler and seed = 42),
followed by manual fine-tuning. The optimized model was trained on the selected isomiR levels from
the UK cohort and validated using the corresponding isomiR levels from the PGB replication cohort.
SHAP[117] were used to identify feature importance within the model and were calculated on the
individual predicted hazard function. HRs, based on SHAP values, were calculated as previously
described[54]. Briefly, Individual SHAP values were exponentiated across features and values were
averaged separately for all patients below feature mean level and those above it. The average value
of above mean levels was divided by the average value of below mean level to yield the hazard ratio.
The performance of the chosen isomiR-based model was compared against alternative models
trained on: reference miRNA levels only, miRNAs levels (defined as the aggregate of all isomiRs
within a miRNA annotation).

NfL assay

NfL levels were quantified using single molecule array (Simoa) technology on the Simoa HD-1
Analyzer (Quanterix) in plasma/serum samples from 152 and 200 patients in the UK discovery and
PGB replication cohorts, respectively. The assay utilized the Simoa NfL Advantage Kit (Quanterix,
#102258), with standards, primary and secondary antibodies, and detection ranges specified by the
manufacturer, including defined lower and upper detection limits. Univariate or multivariate Cox
regression, with or without clinical features, and associations between these and mortality were
analyzed as described below.

Feature engineering

For univariate/multivariate Cox regressions isomiR levels and NfL levels were dichotomized
into

binary variables based on the median levels in the UK discovery cohort. miR-181 levels were
dichotomized using a previously published threshold of 71,000 UMIs [17]. Combinations of isomiR-let-
7g-5p.t with NfL or miR-181 were evaluated by their ratios, followed by a dichotomization based on
the median levels in the UK discovery cohort for NfL combination, or by an in-house algorithm that
evaluated dichotomization cutpoint across all possible values by optimizing univariate Cox mortality
HR on the UK discovery cohort.

miRNA target prediction

mRNA targets of the reference miRNA were retrieved from miRCarta[55], retaining those listed
in at least one of miRTarBase, micro-T-CDS, or TargetScan. Target canonical transcripts sequences
were obtained from Ensembl[118] using *BioPython* V-1.83[119]. miRNA and mRNA sequences were
analyzed using RNA22-v2[56] with a user defined sensitivity-optimized parameters (see Supplementary
Methods). Briefly, lower values of minimum base-pair matches and higher values of free energy were
set to increase prediction of non-canonical targets in addition to allowing 2 mismatches at the miRNA-
mRNA seed pairing and G:U wobbling. Moreover, a higher target detection threshold was chosen
based on predefined program setting. Significant hybridization sites were counted and compared
between the reference miRNA and the isomiR. Targets with differing site counts were analyzed for
enrichment using Enrichr[120-122] via *GSEApy V-1.1.9*[123] and tested against an ALS gene list obtained from
Eitan et al[124].

Quantification and Statistical Analysis

The Student's t-test was applied to assess significant differences in the age at symptom onset or
study enrollment between groups. The Mann–Whitney U test was used to evaluate differences in
ALSFRS-R, DeltaFRS scores, and isomiR-let-7g-5p.t levels between the groups. Differences in the
proportions of censored events, sex prevalence, or Riluzole treatment were tested using a chi-
squared goodness-of-fit test. One-way ANOVA with Tukey-HSD post-hoc analysis assesses
differences in isomiR-let-7g-5p.t levels across ALS sub cohorts and control. The Shapiro-wilk test was
used to determine normal distribution. The Wilcoxon signed-rank test was used to evaluate
enrichment of miRNA targets for ALS genes. Pearson correlation coefficients were calculated to
examine the relationships between isomiR levels within/between the two cohorts. Kaplan–Meier
survival estimators were analyzed using the log-rank Mantel–Cox test, with survival data censored at

a fixed date. Univariate and multivariate Cox proportional hazard models were employed to estimate

mortality hazard ratios from the time of enrollment, and model fit was assessed using the C-index.

Proportional hazard assumptions were assessed by R package *survival* function using the cox.zph

function. The performance of the XGB model was evaluated using the dynamic AUC(t)[125] across the

range of survival periods, the average AUC(t), and the C-index. Specific statistical tests, relevant N

values and their definition, definition of center, and dispersion measures were reported in Tables, and

Figure and Table legends. No sample size estimations were made in this study. All statistical

analyses were conducted, and visualizations were generated using Python (version 3.9.2), R (version

4.0.4), and BioRender.

Parameters to fit models for feature selection

Models for were fitted with the following:

-   Cox: without regularization, ties = 'breslow' and a tolerance of 1e-9.

-   Random Survival Forest: n_estimators = 2, max_depth = 4, max_samples = 0.25,

725   n_estimators = 20, min_samples_split = 2, min_samples_leaf = 2, max_features = 0.5,

726   max_samples = 0.5, min_weight_fraction_leaf = 0.0, max_leaf_nodes = None, bootstrap =

727   True, random_state = 42).

728   -   Survival Gradient Boosting: n_estimators = 20, learning_rate = 0.5, max_depth = 2,

729   subsample = 0.3, loss = 'coxph', criterion = 'friedman_mse', min_samples_split = 2,

730   min_samples_leaf = 1, min_weight_fraction_leaf = 0.0, min_impurity_decrease = 0.0,

731   max_features = None, max_leaf_nodes = None, validation_fraction = 0.1, n_iter_no_change =

732   None, tol = 0.0001, dropout_rate = 0.3, ccp_alpha = 0.0,random_state = 0)

Parameters to fit Tuned survival gradient boosting hyperparameters

n_estimators = 95, learning_rate = 0.1, max_depth = 35 subsample = 0.4545454545454545, loss =

'coxph', criterion = 'friedman_mse', min_samples_split = 60, min_samples_leaf = 20,

min_weight_fraction_leaf = 0.060461799614030046, min_impurity_decrease = 0.6, max_features =

0.1111111111111111, max_leaf_nodes = 100, validation_fraction = 0.1, n_iter_no_change = None,

tol = 0.0001, dropout_rate = 0.016, verbose = 1, ccp_alpha = 0.1, random_state = 42.

Parameters for increased sensitivity analysis of RNA22 v2

Seedmismatchsallowed = 2, seedsize = 8, minpairmatchs = 10, minenergy = -10, maxguwobbles = -

1, and threshold = 3000000

References

1. Pfohl, S.R., Kim, R.B., Coan, G.S., and Mitchell, C.S. (2018). Unraveling the complexity of amyotrophic lateral sclerosis survival prediction. Front. Neuroinform. *12*. 10.3389/fninf.2018.00036.

2. Beghi, E., Chiò, A., Couratier, P., Esteban, J., Hardiman, O., Logroscino, G., Millul, A., Mitchell, D., Preux, P.-M., Pupillo, E., et al. (2011). The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph. Lateral Scler. *12*, 1-10. 10.3109/17482968.2010.502940.

3. Benatar, M., Boylan, K., Jeromin, A., Rutkove, S.B., Berry, J., Atassi, N., and Bruijn, L. (2016). ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve *53*, 169-182. 10.1002/mus.24979.

4. Turner, M.R., Bowser, R., Bruijn, L., Dupuis, L., Ludolph, A., McGrath, M., Manfredi, G., Maragakis, N., Miller, R.G., Pullman, S.L., et al. (2013). Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. *14 Suppl 1*, 19-32. 10.3109/21678421.2013.778554.

5. Shepheard, S.R., Wuu, J., Cardoso, M., Wiklendt, L., Dinning, P.G., Chataway, T., Schultz, D., Benatar, M., and Rogers, M.-L. (2017). Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology *88*, 1137-1143. 10.1212/WNL.0000000000003741.

6. Dergai, O., Wuu, J., Koziczak-Holbro, M., Malaspina, A., Granit, V., Hernandez, J.P., Cooley, A., Sachdev, R., Yu, L., Bidinosti, M., et al. (2025). Skeletal muscle biomarkers of amyotrophic lateral sclerosis: a large-scale, multi-cohort proteomic study. medRxiv. 10.1101/2025.04.23.25326161.

7. Dobrowolny, G., Martone, J., Lepore, E., Casola, I., Petrucci, A., Inghilleri, M., Morlando, M., Colantoni, A., Scicchitano, B.M., Calvo, A., et al. (2021). A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discov *7*, 4. 10.1038/s41420-020-00397-6.

8. Benatar, M., Wuu, J., and Turner, M.R. (2023). Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain *146*, 2711-2716. 10.1093/brain/awac394.

9. Benatar, M., Macklin, E.A., Malaspina, A., Rogers, M.-L., Hornstein, E., Lombardi, V., Renfrey, D., Shepheard, S., Magen, I., Cohen, Y., et al. (2024). Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis. EBioMedicine *108*, 105323. 10.1016/j.ebiom.2024.105323.

10. Lee, R.C., Feinbaum, R.L., and Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell *75*, 843-854. 10.1016/0092-8674(93)90529-y.

11. Haramati, S., Chapnik, E., Sztainberg, Y., Eilam, R., Zwang, R., Gershoni, N., McGlinn, E., Heiser, P.W., Wills, A.-M., Wirguin, I., et al. (2010). miRNA malfunction causes spinal motor neuron disease. Proc. Natl. Acad. Sci. U. S. A. *107*, 13111-13116. 10.1073/pnas.1006151107.

12. Emde, A., Eitan, C., Liou, L.-L., Libby, R.T., Rivkin, N., Magen, I., Reichenstein, I., Oppenheim, H., Eilam, R., Silvestroni, A., et al. (2015). Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. *34*, 2633-2651. 10.15252/embj.201490493.

13. Katsu, M., Hama, Y., Utsumi, J., Takashina, K., Yasumatsu, H., Mori, F., Wakabayashi, K., Shoji, M., and Sasaki, H. (2019). MicroRNA expression profiles of neuron-derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neurosci. Lett. *708*, 134176. 10.1016/j.neulet.2019.03.048.

14.   Reichenstein, I., Eitan, C., Diaz-Garcia, S., Haim, G., Magen, I., Siany, A., Hoye, M.L., Rivkin,
N., Olender, T., Toth, B., et al. (2019). Human genetics and neuropathology suggest a link
between miR-218 and amyotrophic lateral sclerosis pathophysiology. Sci Transl Med *11*.
10.1126/scitranslmed.aav5264.
15.   Toivonen, J.M., Manzano, R., Oliván, S., Zaragoza, P., García-Redondo, A., and Osta, R.
(2014). MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral
sclerosis. PLoS One *9*, e89065. 10.1371/journal.pone.0089065.
16.   Wakabayashi, K., Mori, F., Kakita, A., Takahashi, H., Utsumi, J., and Sasaki, H. (2014).
Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of
amyotrophic lateral sclerosis. Acta Neuropathol Commun *2*, 173. 10.1186/s40478-014-0173-z.
17.   Magen, I., Yacovzada, N.S., Yanowski, E., Coenen-Stass, A., Grosskreutz, J., Lu, C.-H.,
Greensmith, L., Malaspina, A., Fratta, P., and Hornstein, E. (2021). Circulating miR-181 is a
prognostic biomarker for amyotrophic lateral sclerosis. Nat. Neurosci. *24*, 1534-1541.
10.1038/s41593-021-00936-z.
18.   Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Rådmark, O., Kim, S.,
and Kim, V.N. (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature
425, 415-419. 10.1038/nature01957.
19.   Bernstein, E., Caudy, A.A., Hammond, S.M., and Hannon, G.J. (2001). Role for a bidentate
ribonuclease in the initiation step of RNA interference. Nature *409*, 363-366.
10.1038/35053110.
20.   Guo, L., and Chen, F. (2014). A challenge for miRNA: multiple isomiRs in miRNAomics. Gene
544, 1-7. 10.1016/j.gene.2014.04.039.
21.   Morin, R.D., O'Connor, M.D., Griffith, M., Kuchenbauer, F., Delaney, A., Prabhu, A.-L., Zhao,
Y., McDonald, H., Zeng, T., Hirst, M., et al. (2008). Application of massively parallel
sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome
Res. *18*, 610-621. 10.1101/gr.7179508.
22.   Newman, M.A., Mani, V., and Hammond, S.M. (2011). Deep sequencing of microRNA
precursors reveals extensive 3' end modification. RNA *17*, 1795-1803. 10.1261/rna.2713611.
23.   Neilsen, C.T., Goodall, G.J., and Bracken, C.P. (2012). IsomiRs--the overlooked repertoire in
the dynamic microRNAome. Trends Genet. *28*, 544-549. 10.1016/j.tig.2012.07.005.
24.   Kwiatkowski, T.J., Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C.,
Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T., et al. (2009). Mutations in the FUS/TLS
gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science *323*, 1205-
1208. 10.1126/science.1166066.
25.   Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X.,
Smith, B., Ruddy, D., Wright, P., et al. (2009). Mutations in FUS, an RNA processing protein,
cause familial amyotrophic lateral sclerosis type 6. Science *323*, 1208-1211.
10.1126/science.1165942.
26.   Sreedharan, J., Blair, I.P., Tripathi, V.B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall,
J.C., Williams, K.L., Buratti, E., et al. (2008). TDP-43 mutations in familial and sporadic
amyotrophic lateral sclerosis. Science *319*, 1668-1672. 10.1126/science.1154584.
27.   Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E.M., Logroscino, G., Robberecht, W., Shaw,
P.J., Simmons, Z., and van den Berg, L.H. (2017). Amyotrophic lateral sclerosis. Nature
Reviews Disease Primers *3*, 1-19. 10.1038/nrdp.2017.71.
28.   Keuss, M.J., Harley, P., Ryadnov, E., Jackson, R.E., Zanovello, M., Wilkins, O.G., Barattucci,
S., Mehta, P.R., Oliveira, M.G., Parkes, J.E., et al. (2024). Loss of TDP-43 induces synaptic
dysfunction that is rescued by UNC13A splice-switching ASOs. bioRxivorg.
10.1101/2024.06.20.599684.

29. Ma, X.R., Prudencio, M., Koike, Y., Vatsavayai, S.C., Kim, G., Harbinski, F., Briner, A.,
Rodriguez, C.M., Guo, C., Akiyama, T., et al. (2022). TDP-43 represses cryptic exon inclusion
in the FTD-ALS gene UNC13A. Nature *603*, 124-130. 10.1038/s41586-022-04424-7.
30. Melamed, Z.e., López-Erauskin, J., Baughn, M.W., Zhang, O., Drenner, K., Sun, Y.,
Freyermuth, F., McMahon, M.A., Beccari, M.S., Artates, J.W., et al. (2019). Premature
polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent
neurodegeneration. Nature Neuroscience *22*, 180-190. 10.1038/s41593-018-0293-z.
31. Calliari, A., Daughrity, L.M., Albagli, E.A., Castellanos Otero, P., Yue, M., Jansen-West, K.,
Islam, N.N., Caulfield, T., Rawlinson, B., DeTure, M., et al. (2024). HDGFL2 cryptic proteins
report presence of TDP-43 pathology in neurodegenerative diseases. Molecular
Neurodegeneration *19*, 1-5. 10.1186/s13024-024-00718-8.
32. Irwin, K.E., Jasin, P., Braunstein, K.E., Sinha, I.R., Garret, M.A., Bowden, K.D., Chang, K.,
Troncoso, J.C., Moghekar, A., Oh, E.S., et al. (2024). A fluid biomarker reveals loss of TDP-43
splicing repression in presymptomatic ALS–FTD. Nature Medicine *30*, 382-393.
10.1038/s41591-023-02788-5.
33. Chen, X., Fan, Z., McGee, W., Chen, M., Kong, R., Wen, P., Xiao, T., Chen, X., Liu, J., Zhu,
L., et al. (2018). TDP-43 regulates cancer-associated microRNAs. Protein Cell *9*, 848-866.
10.1007/s13238-017-0480-9.
34. Morlando, M., Dini Modigliani, S., Torrelli, G., Rosa, A., Di Carlo, V., Caffarelli, E., and
Bozzoni, I. (2012). FUS stimulates microRNA biogenesis by facilitating co-transcriptional
Drosha recruitment: FUS participates in microRNA biogenesis. EMBO J. *31*, 4502-4510.
10.1038/emboj.2012.319.
35. Porta, S., Kwong, L.K., Trojanowski, J.Q., and Lee, V.M.Y. (2015). Drosha inclusions are new
components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion
cases. J. Neuropathol. Exp. Neurol. *74*, 380-387. 10.1097/NEN.0000000000000182.
36. Aiso, T., and Ueda, M. (2023). 5'‐isomiR is the most abundant sequence of miR‐1246, a
candidate biomarker of lung cancer, in serum. Mol. Med. Rep. *27*. 10.3892/mmr.2023.12979.
37. Ibuki, Y., Nishiyama, Y., Tsutani, Y., Emi, M., Hamai, Y., Okada, M., and Tahara, H. (2020).
Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma.
PLoS One *15*, e0231116. 10.1371/journal.pone.0231116.
38. Koppers-Lalic, D., Hackenberg, M., de Menezes, R., Misovic, B., Wachalska, M., Geldof, A.,
Zini, N., de Reijke, T., Wurdinger, T., Vis, A., et al. (2016). Non‐invasive prostate cancer
detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget
7, 22566-22578. 10.18632/oncotarget.8124.
39. Lan, C., Peng, H., McGowan, E.M., Hutvagner, G., and Li, J. (2018). An isomiR expression
panel based novel breast cancer classification approach using improved mutual information.
BMC Med. Genomics *11*, 118. 10.1186/s12920-018-0434-y.
40. Wang, S., Zheng, Z., Chen, P., and Wu, M. (2019). Tumor classification and biomarker
discovery based on the 5'isomiR expression level. BMC Cancer *19*, 127. 10.1186/s12885-
019-5340-y.
41. Loher, P., Londin, E., Ilieva, H., Pasinelli, P., and Rigoutsos, I. (2025). Re-Analyses of
Samples From Amyotrophic Lateral Sclerosis Patients and Controls Identify Many Novel Small
RNAs With Diagnostic And Prognostic Potential. Molecular Neurobiology *62*, 8135-8149.
10.1007/s12035-025-04747-2.
42. Cox, D.R. (1972). Regression Models and Life-Tables. J. R. Stat. Soc. Series B Stat.
Methodol. *34*, 187-202. 10.1111/j.2517-6161.1972.tb00899.x.
43. Hothorn, T., Bühlmann, P., Dudoit, S., Molinaro, A., and Van Der Laan, M.J. (2005). Survival
ensembles. Biostatistics *7*, 355-373. 10.1093/biostatistics/kxj011.

44. Ishwaran, H., Gerds, T.A., Kogalur, U.B., Moore, R.D., Gange, S.J., and Lau, B.M. (2014).
Random survival forests for competing risks. Biostatistics *15*, 757-773.
10.1093/biostatistics/kxu010.
45. Breiman, L. (1996). Bagging predictors. Mach. Learn. *24*, 123-140. 10.1007/BF00058655.
46. Džeroski, S., and Ženko, B. (2004). Is Combining Classifiers with Stacking Better than
Selecting the Best One? Mach. Learn. *54*, 255-273. 10.1023/B:MACH.0000015881.36452.6e.
47. Malviya, R., Ghinea, G., Dhanaraj, R.K., Balusamy, B., and Sundram, S. (2022). Deep
Learning for Targeted Treatments: Transformation in Healthcare (John Wiley & Sons).
48. Faure, H., and Hrynaszkiewicz, I. (2011). The ISRCTN Register: achievements and
challenges 8 years on: The ISRCTN Register. J. Evid. Based Med. *4*, 188-192.
10.1111/j.1756-5391.2011.01138.x.
49. ClinicalTrials.gov/study/NCT02327845. https://clinicaltrials.gov/study/NCT02327845.
50. Magen, I., Yacovzada, N.-S., Warren, J.D., Heller, C., Swift, I., Bobeva, Y., Malaspina, A.,
Rohrer, J.D., Fratta, P., and Hornstein, E. (2023). microRNA-based predictor for diagnosis of
frontotemporal dementia. Neuropathol. Appl. Neurobiol., e12916. 10.1111/nan.12916.
51. Charilaou, P., and Battat, R. (2022). Machine learning models and over-fitting considerations.
World J Gastroenterol *28*, 605-607. 10.3748/wjg.v28.i5.605.
52. Taylor, J.M.G., Ankerst, D.P., and Andridge, R.R. (2008). Validation of biomarker-based risk
prediction models. Clin Cancer Res *14*, 5977-5983. 10.1158/1078-0432.CCR-07-4534.
53. Thorndike, R.L. (1953). Who belongs in the family? Psychometrika *18*, 267-276.
10.1007/BF02289263.
54. Sundrani, S., and Lu, J. (2021). Computing the hazard ratios associated with explanatory
variables using machine learning models of survival data. JCO Clin. Cancer Inform. *5*, 364-
378. 10.1200/CCI.20.00172.
55. Backes, C., Fehlmann, T., Kern, F., Kehl, T., Lenhof, H.P., Meese, E., and Keller, A. (2018).
miRCarta: a central repository for collecting miRNA candidates. Nucleic Acids Res *46*, D160-
D167. 10.1093/nar/gkx851.
56. Miranda, K.C., Huynh, T., Tay, Y., Ang, Y.S., Tam, W.L., Thomson, A.M., Lim, B., and
Rigoutsos, I. (2006). A pattern-based method for the identification of MicroRNA binding sites
and their corresponding heteroduplexes. Cell *126*, 1203-1217. 10.1016/j.cell.2006.07.031.
57. Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni,
G., Fratta, P., Sidle, K., Fish, M., et al. (2015). Neurofilament light chain: A prognostic
biomarker in amyotrophic lateral sclerosis. Neurology *84*, 2247-2257.
10.1212/WNL.0000000000001642.
58. Banack, S.A., Dunlop, R.A., Stommel, E.W., Mehta, P., and Cox, P.A. (2022). miRNA
extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis. J
Neurol Sci *442*, 120396. 10.1016/j.jns.2022.120396.
59. de Andrade, H.M.T., de Albuquerque, M., Avansini, S.H., de S Rocha, C., Dogini, D.B., Nucci,
A., Carvalho, B., Lopes-Cendes, I., and França, M.C., Jr. (2016). MicroRNAs-424 and 206 are
potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J. Neurol. Sci. *368*,
19-24. 10.1016/j.jns.2016.06.046.
60. Figueroa-Romero, C., Hur, J., Lunn, J.S., Paez-Colasante, X., Bender, D.E., Yung, R.,
Sakowski, S.A., and Feldman, E.L. (2016). Expression of microRNAs in human post-mortem
amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol Cell
Neurosci *71*, 34-45. 10.1016/j.mcn.2015.12.008.
61. Hur, J., Paez-Colasante, X., Figueroa-Romero, C., Lo, T.W., Barmada, S.J., Paulsen, M.T.,
Ljungman, M., Alakwaa, F.M., Savelieff, M.G., Goutman, S.A., and Feldman, E.L. (2023).
miRNA analysis reveals novel dysregulated pathways in amyotrophic lateral sclerosis. Hum
Mol Genet *32*, 934-947. 10.1093/hmg/ddac250.

62. Kawahara, Y., and Mieda-Sato, A. (2012). TDP-43 promotes microRNA biogenesis as a
component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci. U. S. A. *109*, 3347-
3352. 10.1073/pnas.1112427109.
63. Liguori, M., Nuzziello, N., Introna, A., Consiglio, A., Licciulli, F., D'Errico, E., Scarafino, A.,
Distaso, E., and Simone, I.L. (2018). Dysregulation of MicroRNAs and Target Genes
Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis. Front.
Mol. Neurosci. *11*, 288. 10.3389/fnmol.2018.00288.
64. Maimon, R., Ionescu, A., Bonnie, A., Sweetat, S., Wald-Altman, S., Inbar, S., Gradus, T.,
Trotti, D., Weil, M., Behar, O., and Perlson, E. (2018). miR126-5p Downregulation Facilitates
Axon Degeneration and NMJ Disruption via a Non-Cell-Autonomous Mechanism in ALS. J
Neurosci *38*, 5478-5494. 10.1523/JNEUROSCI.3037-17.2018.
65. Raheja, R., Regev, K., Healy, B.C., Mazzola, M.A., Beynon, V., Von Glehn, F., Paul, A., Diaz-
Cruz, C., Gholipour, T., Glanz, B.I., et al. (2018). Correlating serum micrornas and clinical
parameters in amyotrophic lateral sclerosis. Muscle Nerve *58*, 261-269. 10.1002/mus.26106.
66. Saucier, D., Wajnberg, G., Roy, J., Beauregard, A.-P., Chacko, S., Crapoulet, N., Fournier, S.,
Ghosh, A., Lewis, S.M., Marrero, A., et al. (2019). Identification of a circulating miRNA
signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain
Res. *1708*, 100-108. 10.1016/j.brainres.2018.12.016.
67. Koval, E.D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B.N., Wu, G.F.,
and Miller, T.M. (2013). Method for widespread microRNA-155 inhibition prolongs survival in
ALS-model mice. Hum Mol Genet *22*, 4127-4135. 10.1093/hmg/ddt261.
68. Ma, H., Wu, Y., Niu, Q., Zhang, J., Jia, G., Manjunath, N., and Wu, H. (2016). A sliding-bulge
structure at the Dicer processing site of pre-miRNAs regulates alternative Dicer processing to
generate 5'-isomiRs. Heliyon *2*, e00148. 10.1016/j.heliyon.2016.e00148.
69. Kour, S., Fortuna, T., Anderson, E.N., Mawrie, D., Bilstein, J., Sivasubramanian, R., Ward, C.,
Roy, R., Rajasundaram, D., Sterneckert, J., and Pandey, U.B. (2023). Drosha-dependent
microRNAs modulate FUS-mediated neurodegeneration in vivo. Nucleic Acids Res *51*, 11258-
11276. 10.1093/nar/gkad774.
70. Kmetzsch, V., Latouche, M., Saracino, D., Rinaldi, D., Camuzat, A., Gareau, T., French
Research Network on, F.A., Le Ber, I., Colliot, O., and Becker, E. (2022). MicroRNA
signatures in genetic frontotemporal dementia and amyotrophic lateral sclerosis. Ann. Clin.
Transl. Neurol. *9*, 1778-1791. 10.1002/acn3.51674.
71. Aharon, A., Spector, P., Ahmad, R.S., Horrany, N., Sabbach, A., Brenner, B., and Aharon-
Peretz, J. (2020). Extracellular vesicles of Alzheimer's disease patients as a biomarker for
disease progression. Mol. Neurobiol. *57*, 4156-4169. 10.1007/s12035-020-02013-1.
72. Kumar, P., Dezso, Z., MacKenzie, C., Oestreicher, J., Agoulnik, S., Byrne, M., Bernier, F.,
Yanagimachi, M., Aoshima, K., and Oda, Y. (2013). Circulating miRNA biomarkers for
Alzheimer's disease. PLoS One *8*, e69807. 10.1371/journal.pone.0069807.
73. Mendes-Silva, A.P., Pereira, K.S., Tolentino-Araujo, G.T., Nicolau, E.d.S., Silva-Ferreira,
C.M., Teixeira, A.L., and Diniz, B.S. (2016). Shared biologic pathways between Alzheimer
disease and major depression: A systematic review of MicroRNA expression studies. Am. J.
Geriatr. Psychiatry *24*, 903-912. 10.1016/j.jagp.2016.07.017.
74. Satoh, J.-I., Kino, Y., and Niida, S. (2015). MicroRNA-Seq data analysis pipeline to identify
blood biomarkers for Alzheimer's disease from public data. Biomark. Insights *10*, 21-31.
10.4137/BMI.S25132.
75. Tan, L., Yu, J.-T., Tan, M.-S., Liu, Q.-Y., Wang, H.-F., Zhang, W., Jiang, T., and Tan, L.
(2014). Genome-wide serum microRNA expression profiling identifies serum biomarkers for
Alzheimer's disease. J. Alzheimers. Dis. *40*, 1017-1027. 10.3233/JAD-132144.

76. Zhang, X., Wang, Y., Liu, W., Wang, T., Wang, L., Hao, L., Ju, M., and Xiao, R. (2021). Diet
quality, gut microbiota, and microRNAs associated with mild cognitive impairment in middle-
aged and elderly Chinese population. Am. J. Clin. Nutr. *114*, 429-440. 10.1093/ajcn/nqab078.
77. Zhang, X., Xi, Y., Yu, H., An, Y., Wang, Y., Tao, L., Wang, Y., Liu, W., Wang, T., and Xiao, R.
(2019). 27-hydroxycholesterol promotes Aβ accumulation via altering Aβ metabolism in mild
cognitive impairment patients and APP/PS1 mice: 27-hydroxycholesterol leads to cognitive
dysfunction via Aβ. Brain Pathol. *29*, 558-573. 10.1111/bpa.12698.
78. Kafshdooz, T., Farajnia, S., Sharifi, R., and Najmi, S. (2023). Hsa-let-7g-5p, a circulating
microRNA, as a biomarker for Alzheimer's disease. Inform. Med. Unlocked *38*, 101203.
10.1016/j.imu.2023.101203.
79. Martí, E., Pantano, L., Bañez-Coronel, M., Llorens, F., Miñones-Moyano, E., Porta, S.,
Sumoy, L., Ferrer, I., and Estivill, X. (2010). A myriad of miRNA variants in control and
Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids
Res. *38*, 7219-7235. 10.1093/nar/gkq575.
80. Awuson-David, B., Williams, A.C., Wright, B., Hill, L.J., and Di Pietro, V. (2023). Common
microRNA regulated pathways in Alzheimer's and Parkinson's disease. Front Neurosci *17*,
1228927. 10.3389/fnins.2023.1228927.
81. Daneshafrooz, N., Joghataei, M.T., Mehdizadeh, M., Alavi, A., Barati, M., Panahi, B.,
Teimourian, S., and Zamani, B. (2022). Identification of let-7f and miR-338 as plasma-based
biomarkers for sporadic amyotrophic lateral sclerosis using meta-analysis and empirical
validation. Sci Rep *12*, 1373. 10.1038/s41598-022-05067-4.
82. Durur, D.Y., Tastan, B., Ugur Tufekci, K., Olcum, M., Uzuner, H., Karakulah, G., Yener, G.,
and Genc, S. (2022). Alteration of miRNAs in Small Neuron-Derived Extracellular Vesicles of
Alzheimer's Disease Patients and the Effect of Extracellular Vesicles on Microglial Immune
Responses. J Mol Neurosci *72*, 1182-1194. 10.1007/s12031-022-02012-y.
83. Gamez-Valero, A., Campdelacreu, J., Vilas, D., Ispierto, L., Rene, R., Alvarez, R., Armengol,
M.P., Borras, F.E., and Beyer, K. (2019). Exploratory study on microRNA profiles from
plasma-derived extracellular vesicles in Alzheimer's disease and dementia with Lewy bodies.
Transl Neurodegener *8*, 31. 10.1186/s40035-019-0169-5.
84. Gui, Y., Liu, H., Zhang, L., Lv, W., and Hu, X. (2015). Altered microRNA profiles in
cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget *6*,
37043-37053. 10.18632/oncotarget.6158.
85. Lehmann, S.M., Kruger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart, J., Trimbuch,
T., Eom, G., Hinz, M., Kaul, D., et al. (2012). An unconventional role for miRNA: let-7 activates
Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci *15*, 827-835.
10.1038/nn.3113.
86. Liu, Y., He, X., Li, Y., and Wang, T. (2018). Cerebrospinal fluid CD4+ T lymphocyte-derived
miRNA-let-7b can enhances the diagnostic performance of Alzheimer's disease biomarkers.
Biochem Biophys Res Commun *495*, 1144-1150. 10.1016/j.bbrc.2017.11.122.
87. Poursaei, E., Abolghasemi, M., Bornehdeli, S., Shanehbandi, D., Asadi, M., Sadeghzadeh, M.,
Rahmanpour, D., and Sadeh, R.N. (2022). Evaluation of hsa-let-7d-5p, hsa-let-7g-5p and hsa-
miR-15b-5p plasma levels in patients with Alzheimer's disease. Psychiatr Genet *32*, 25-29.
10.1097/YPG.0000000000000303.
88. Samareh, A., Nematollahi, M.H., Pourghadamyari, H., Meimand, H.A.E., Shabani, M., and
Asadikaram, G. (2024). Diagnostic Potential of NEAT1, hsa-let-7a-5p, and miR-506-3p in
Early-stage Parkinson's Disease. Curr Med Chem.
10.2174/0109298673336756241016063552.
89. van Harten, A.C., Mulders, J., Scheltens, P., van der Flier, W.M., and Oudejans, C.B. (2015).
Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for
Alzheimer's Disease. J Alzheimers Dis *47*, 243-252. 10.3233/JAD-140075.

90. Vrabec, K., Bostjancic, E., Koritnik, B., Leonardis, L., Dolenc Groselj, L., Zidar, J., Rogelj, B.,
Glavac, D., and Ravnik-Glavac, M. (2018). Differential Expression of Several miRNAs and the
Host Genes AATK and DNM2 in Leukocytes of Sporadic ALS Patients. Front Mol Neurosci *11*,
106. 10.3389/fnmol.2018.00106.
91. Lin, Z., Ge, J., Wang, Z., Ren, J., Wang, X., Xiong, H., Gao, J., Zhang, Y., and Zhang, Q.
(2017). Let-7e modulates the inflammatory response in vascular endothelial cells through
ceRNA crosstalk. Scientific Reports *7*, 1-12. 10.1038/srep42498.
92. Liu, Q., Hu, Y., Zhang, M., Yan, Y., Yu, H., and Ge, L. (2018). microRNA-451 protects
neurons against ischemia/reperfusion injury-induced cell death by targeting CELF2.
Neuropsychiatr. Dis. Treat. *14*, 2773-2782. 10.2147/NDT.S173632.
93. Luo, Q., Zhu, J., Zhang, Q., Xie, J., Yi, C., and Li, T. (2020). MicroRNA-486-5p Promotes
Acute Lung Injury via Inducing Inflammation and Apoptosis by Targeting OTUD7B.
Inflammation *43*, 975-984. 10.1007/s10753-020-01183-3.
94. Ma, N., Li, S., Lin, C., Cheng, X., and Meng, Z. (2021). Mesenchymal stem cell conditioned
medium attenuates oxidative stress injury in hepatocytes partly by regulating the miR-486-
5p/PIM1 axis and the TGF-β/Smad pathway. Bioengineered *12*, 6434-6447.
10.1080/21655979.2021.1972196.
95. Mandolesi, G., De Vito, F., Musella, A., Gentile, A., Bullitta, S., Fresegna, D., Sepman, H., Di
Sanza, C., Haji, N., Mori, F., et al. (2017). MiR-142-3p is a key regulator of IL-1β-dependent
synaptopathy in neuroinflammation. J. Neurosci. *37*, 546-561. 10.1523/jneurosci.0851-
16.2017.
96. Strycharz, J., Wróblewski, A., Zieleniak, A., Świderska, E., Matyjas, T., Rucińska, M.,
Pomorski, L., Czarny, P., Szemraj, J., Drzewoski, J., and Śliwińska, A. (2021). Visceral
adipose tissue of prediabetic and diabetic females shares a set of similarly upregulated
microRNAs functionally annotated to inflammation, oxidative stress and insulin signaling.
Antioxidants (Basel) *10*, 101. 10.3390/antiox10010101.
97. Tan, W., Gu, Z., Leng, J., Zou, X., Chen, H., Min, F., Zhou, W., Zhang, L., and Li, G. (2019).
Let-7f-5p ameliorates inflammation by targeting NLRP3 in bone marrow-derived mesenchymal
stem cells in patients with systemic lupus erythematosus. Biomed Pharmacother *118*, 109313.
10.1016/j.biopha.2019.109313.
98. Thomas, J.J., Harp, K.O., Bashi, A., Hood, J.L., Botchway, F., Wilson, M.D., Thompson, W.E.,
Stiles, J.K., and Driss, A. (2022). MiR-451a and let-7i-5p loaded extracellular vesicles
attenuate heme-induced inflammation in hiPSC-derived endothelial cells. Front. Immunol. *13*,
1082414. 10.3389/fimmu.2022.1082414.
99. Gan, X., Zhao, H., Wei, Y., Jiang, Q., Wen, C., and Ying, Y. (2020). Role of miR-92a-3p,
oxidative stress, and p38MAPK/NF-κB pathway in rats with central venous catheter related
thrombosis. BMC Cardiovascular Disorders *20*, 1-8. 10.1186/s12872-020-01436-x.
100. Dika, E., Broseghini, E., Porcellini, E., Lambertini, M., Riefolo, M., Durante, G., Loher, P.,
Roncarati, R., Bassi, C., Misciali, C., et al. (2021). Unraveling the role of microRNA/isomiR
network in multiple primary melanoma pathogenesis. Cell Death Dis *12*, 473. 10.1038/s41419-
021-03764-y.
101. Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., and Burge, C.B. (2003). Prediction
of mammalian microRNA targets. Cell *115*, 787-798. 10.1016/s0092-8674(03)01018-3.
102. Wong, L.L., Fadzil, A.B., Chen, Q., Rademaker, M.T., Charles, C.J., Richards, A.M., and
Wang, P. (2023). Interrogating the Role of miR-125b and Its 3'isomiRs in Protection against
Hypoxia. Int J Mol Sci *24*. 10.3390/ijms242116015.
103. Yu, F., Pillman, K.A., Neilsen, C.T., Toubia, J., Lawrence, D.M., Tsykin, A., Gantier, M.P.,
Callen, D.F., Goodall, G.J., and Bracken, C.P. (2017). Naturally existing isoforms of miR-222
have distinct functions. Nucleic Acids Res *45*, 11371-11385. 10.1093/nar/gkx788.

104. Strong, M.J., Abrahams, S., Goldstein, L.H., Woolley, S., McLaughlin, P., Snowden, J.,
Mioshi, E., Roberts-South, A., Benatar, M., HortobáGyi, T., et al. (2017). Amyotrophic lateral
sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.
Amyotroph Lateral Scler Frontotemporal Degener *18*, 153-174.
10.1080/21678421.2016.1267768.
105. Abrahams, S., Newton, J., Niven, E., Foley, J., and Bak, T.H. (2014). Screening for cognition
and behaviour changes in ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. *15*, 9-14.
10.3109/21678421.2013.805784.
106. Cedarbaum, J.M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., and Nakanishi, A.
(1999). The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments
of respiratory function. BDNF ALS Study Group (Phase III). J. Neurol. Sci. *169*, 13-21.
10.1016/s0022-510x(99)00210-5.
107. Coenen-Stass, A.M.L., Magen, I., Brooks, T., Ben-Dov, I.Z., Greensmith, L., Hornstein, E.,
and Fratta, P. (2018). Evaluation of methodologies for microRNA biomarker detection by next
generation sequencing. RNA Biol. *15*, 1133-1145. 10.1080/15476286.2018.1514236.
108. Kohen, R., Barlev, J., Hornung, G., Stelzer, G., Feldmesser, E., Kogan, K., Safran, M., and
Leshkowitz, D. (2019). UTAP: User-friendly Transcriptome Analysis Pipeline. BMC
Bioinformatics *20*, 154. 10.1186/s12859-019-2728-2.
109. Kozomara, A., and Griffiths-Jones, S. (2014). miRBase: annotating high confidence
microRNAs using deep sequencing data. Nucleic Acids Res. *42*, D68-73.
10.1093/nar/gkt1181.
110. Ewing, B., and Green, P. (1998). Base-calling of automated sequencer traces using phred. II.
Error probabilities. Genome Res. *8*, 186-194. 10.1101/gr.8.3.186.
111. Lall, R., and Robinson, T. Efficient Multiple Imputation for Diverse Data in Python and R:
MIDASpy and rMIDAS.
112. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. *15*, 550. 10.1186/s13059-014-0550-
8.
113. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva package
for removing batch effects and other unwanted variation in high-throughput experiments.
Bioinformatics *28*, 882-883. 10.1093/bioinformatics/bts034.
114. Pudil, P., Novovičová, J., and Kittler, J. (1994). Floating search methods in feature selection.
Pattern Recognit. Lett. *15*, 1119-1125. 10.1016/0167-8655(94)90127-9.
115. Raschka, S. (2018). MLxtend: Providing machine learning and data science utilities and
extensions to Python's scientific computing stack. Journal of Open Source Software *3*, 638.
10.21105/joss.00638.
116. Akiba, T., Sano, S., Yanase, T., Ohta, T., and Koyama, M. (2019). Optuna: A next-generation
hyperparameter optimization framework. Proceedings of the 25th ACM SIGKDD International
Conference on Knowledge Discovery & Data Mining. ACM.
117. Lundberg, S., and Lee, S.-I. (2017). A unified approach to interpreting model predictions. arXiv
[cs.AI].
118. Yates, A.D., Achuthan, P., Akanni, W., Allen, J., Allen, J., Alvarez-Jarreta, J., Amode, M.R.,
Armean, I.M., Azov, A.G., Bennett, R., et al. (2020). Ensembl 2020. Nucleic Acids Res *48*,
D682-D688. 10.1093/nar/gkz966.
119. Cock, P.J., Antao, T., Chang, J.T., Chapman, B.A., Cox, C.J., Dalke, A., Friedberg, I.,
Hamelryck, T., Kauff, F., Wilczynski, B., and de Hoon, M.J. (2009). Biopython: freely available
Python tools for computational molecular biology and bioinformatics. Bioinformatics *25*, 1422-
1423. 10.1093/bioinformatics/btp163.

120.   Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and
1133   Ma'ayan, A. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment
1134   analysis tool. BMC Bioinformatics *14*, 128. 10.1186/1471-2105-14-128.
1135   121.   Kuleshov, M.V., Jones, M.R., Rouillard, A.D., Fernandez, N.F., Duan, Q., Wang, Z., Koplev,
1136   S., Jenkins, S.L., Jagodnik, K.M., Lachmann, A., et al. (2016). Enrichr: a comprehensive gene
1137   set enrichment analysis web server 2016 update. Nucleic Acids Res *44*, W90-97.
1138   10.1093/nar/gkw377.
1139   122.   Xie, Z., Bailey, A., Kuleshov, M.V., Clarke, D.J.B., Evangelista, J.E., Jenkins, S.L., Lachmann,
1140   A., Wojciechowicz, M.L., Kropiwnicki, E., Jagodnik, K.M., et al. (2021). Gene Set Knowledge
1141   Discovery with Enrichr. Curr Protoc *1*, e90. 10.1002/cpz1.90.
1142   123.   Fang, Z., Liu, X., and Peltz, G. (2023). GSEApy: a comprehensive package for performing
1143   gene set enrichment analysis in Python. Bioinformatics *39*. 10.1093/bioinformatics/btac757.
1144   124.   Eitan, C., Siany, A., Barkan, E., Olender, T., van Eijk, K.R., Moisse, M., Farhan, S.M.K.,
1145   Danino, Y.M., Yanowski, E., Marmor-Kollet, H., et al. (2022). Whole-genome sequencing
1146   reveals that variants in the Interleukin 18 Receptor Accessory Protein 3'UTR protect against
1147   ALS. Nat Neurosci *25*, 433-445. 10.1038/s41593-022-01040-6.
1148   125.   Lambert, J., and Chevret, S. (2016). Summary measure of discrimination in survival models
1149   based on cumulative/dynamic time-dependent ROC curves. Stat Methods Med Res *25*, 2088-
1150   2102. 10.1177/0962280213515571.
1151

	UK – discovery (N = 154)	PGB – replication (N = 200)	Overall (N = 354)
Sex:			
Males	91 (59%)	90 (45%)	181 (51%)
Females	63 (41%)	110 (55%)	173 (49%)
Age at symptom onset (years) (Mean ± SD)	62.3 (± 11)	57 (± 12)	59.3 (± 12)
Age at enrollment (years) (Mean ± SD)	63.9 (± 11)	58.4 (± 12)	60.8 (± 12)
Disease duration at enrollment (months) (Mean ± SD)	19.3 (± 10)	16.5 (± 8)	17.7 (± 9)
Baseline ALSFRS-R (AU) (Median [Q1, Q3])	38 [33, 43]	39 [35, 41]	39 [34, 42]
DeltaFRS (-ALSFRS-R unit / month) (Median [Q1, Q3])	0.6 [0.3, 0.9]	0.6 [0.4, 0.9]	0.6 [0.3, 0.9]
Site of symptom onset			
Bulbar	52 (34%)	55 (28%)	107 (30%)
Non-bulbar	102 (66%)	145 (72%)	247 (70%)
C9orf72 status			
Carrier	12 (8%)	20 (10%)	32 (9%)
Non-carrier	142 (92%)	180 (90%)	322 (91%)
Riluzole treatment			
Yes	109 (71%)	134 (67%)	243 (69%)
No	45 (29%)	66 (33%)	111 (31%)
Survival from symptom onset (months) (Median [Q1, Q3])	33 [26.7, 46.7]	33.4 [22.5, 43.9]	33 [23.7, 44.5]
Survival from enrollment (months) (Median [Q1, Q3])	13.9 [8.9, 23.9]	14.7 [8.5, 24.1]	14.3 [8.7, 24.1]
Censored event			
Yes	9 (6%)	108 (54%)	117 (33%)
No	145 (94%)	92 (46%)	237 (67%)

Cohort

■ UK discovery   ■ PGB replication

A isomiR

Time-dependent AUC

Months from enrollment

B miRNA

Time-dependent AUC

Months from enrollment

C Reference miRNA

Time-dependent AUC

Months from enrollment

D

Average AUC-t

isomiRs   miRNA   Reference miRNA

E

C - index

isomiRs   miRNA   Reference miRNA

F UK - discovery

isomiR-92a-3p.T22C
isomiR-let-7g-5p.t
isomiR-92a-3p.T1C
isomiR-let-7f-5p.T16C.t
isomiR-let-7i-5p.G5A
isomiR-146a-5p.T22A
isomiR-144-3p
isomiR-432-5p
isomiR-130b-5p.T
isomiR-451a.T.A
isomiR-let-7e-5p.G9C
isomiR-425-5p.as
isomiR-142-3p.a
isomiR-151a-3p.A9G
isomiR-486-5p.C
isomiR-30d-5p.A20G.CT
isomiR-25-3p.A22T
isomiR-486-5p.T9G.T

SHAP Value

G PGB - replication

isomiR-92a-3p.T22C
isomiR-let-7g-5p.t
isomiR-92a-3p.T1C
isomiR-let-7f-5p.T16C.t
isomiR-let-7i-5p.G5A
isomiR-146a-5p.T22A
isomiR-432-5p
isomiR-144-3p
isomiR-130b-5p.T
isomiR-451a.T.A
isomiR-let-7e-5p.G9C
isomiR-425-5p.as
isomiR-142-3p.a
isomiR-151a-3p.A9G
isomiR-486-5p.C
isomiR-30d-5p.A20G.CT
isomiR-25-3p.A22T
isomiR-486-5p.T9G.T

SHAP Value

Feature Value

H SHAP based HRs

isomiR-92a-3p.T22C
isomiR-let-7g-5p.t
isomiR-92a-3p.T1C
isomiR-let-7f-5p.T16C.t
isomiR-let-7i-5p.G5A
isomiR-146a-5p.T22A
isomiR-144-3p
isomiR-432-5p
isomiR-130b-5p.T
isomiR-451a.T.A
isomiR-let-7e-5p.G9C
isomiR-425-5p.as
isomiR-142-3p.a
isomiR-151a-3p.A9G
isomiR-486-5p.C
isomiR-30d-5p.A20G.CT
isomiR-25-3p.A22T
isomiR-486-5p.T9G.T

0.915   1.000   1.110
HR